keyword
MENU ▼
Read by QxMD icon Read
search

Statins and NASH

keyword
https://www.readbyqxmd.com/read/29452601/reactive-hyperemia-index-rhi-and-cognitive-performance-indexes-are-associated-with-histologic-markers-of-liver-disease-in-subjects-with-non-alcoholic-fatty-liver-disease-nafld-a-case-control-study
#1
Antonino Tuttolomondo, Salvatore Petta, Alessandra Casuccio, Carlo Maida, Vittoriano Della Corte, Mario Daidone, Domenico Di Raimondo, Rosaria Pecoraro, Roberto Fonte, Anna Cirrincione, Rita Zafonte, Daniela Cabibi, Calogero Cammà, Vito Di Marco, Anna Licata, Franco Magliozzo, Giulio Marchesini, Giovanni Merlino, Antonio Craxì, Antonio Pinto
BACKGROUND: No study evaluated vascular health markers in subjects with non-alcoholic fatty liver disease (NAFLD) through a combined analysis of reactive hyperemia peripheral arterial tonometry (RH-PAT) and arterial stiffness indexes. AIM OF THE STUDY: We aimed to assess whether NAFLD and its histological severity are associated with impairment of arterial stiffness and RH-PAT indexes in a mixed cohort of patients with biopsy-proven NAFLD. MATERIALS AND METHODS: The Kleiner classification was used to grade NAFLD grade...
February 16, 2018: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29344336/treating-nonalcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes-mellitus-a-review-of-efficacy-and-safety
#2
REVIEW
Elizabeth P Mills, K Paige D Brown, Jennifer D Smith, Phillip W Vang, Katie Trotta
Objective: To review current literature for the efficacy and safety of treatment for nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Data sources: A PubMed literature search from January 1990 to June 2017 was conducted using the search terms nonalcoholic fatty liver disease, diabetes mellitus, type 2, therapy, treatment, treat, therapeutics, nonalcoholic fatty liver, nonalcoholic hepatosteatosis, NASH, NAFLD, metformin, and statin...
January 2018: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29231919/-non-alcoholic-liver-disease-diagnosis-and-treatment
#3
REVIEW
Anna Sarosiekjeznach-Steinhagen, Joanna Ostrowska, Aneta Czerwonogrodzka-Senczyna, Iwona Boniecka
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in the developed world (15% to 40% of the adult population). Introduction of lifestyle changes including dietary intervention and increased physical activity is most often the first-line treatment and is intended to support not only the treatment of liver disease, but also for diseases associated with obesity, insulin resistance, diabetes and dyslipidemia. In addition to well-known metformin, there are new classes of antidiabetic drugs, including GLP-1analog, SGLT-2 antagonist, pioglitazon...
November 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29204050/current-and-emerging-pharmacological-therapy-for-non-alcoholic-fatty-liver-disease
#4
EDITORIAL
Ahad Eshraghian
The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modification may need pharmacological therapy. One major obstacle is measurement of histological outcome by liver biopsy which is an invasive method and is not recommended routinely in these patients...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28676027/the-co-existence-of-nash-and-chronic-kidney-disease-boosts-cardiovascular-risk-are-there-any-common-therapeutic-options
#5
Marianna Papademetriou, Vasilios G Athyros, Eleni Geladari, Michael Doumas, Costas Tsioufis, Vasilios Papademetriou
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease. NAFLD may evolve to non-alcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD) mortality. There is no generally accepted effective treatment for NAFLD/NASH. Chronic kidney disease (CKD) is relatively common and might co-exist with NAFLD/NASH, aggravate one another, and increase CVD risk. Common therapies could improve outcome. Potent statins at high doses, such as atorvastatin and rosuvastatin, ameliorate NAFLD/NASH and reduce the mortality rates by half as compared with those on the same statins but without liver disease and CVD-related events are reduced by atorvastatin for patients with all stages of CKD...
2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676026/a-critical-approach-of-guideline-therapeutic-recommendations-for-nafld
#6
Dragan B Djordjevic, Marija Zdravkovic, Aleksandar Nagorni, Athanasios Manolis, Costas Tsioufis, Dragan Lovic
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as progressive form of the disease are associated with cardiovascular risk factors including obesity, dyslipidaemia, hyperglycaemia and hypertension. When NAFLD is associated with cardiovascular disease, mortality of NAFLD patients is increased due to cardiovascular disease. Prevalence of NAFLD and NASH is high, but it seems that epidemic of the disease is under-recognized and under-appreciated. Linking pathophysiological mechanisms are complex and still not well understood...
2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676020/current-and-potential-future-pharmacological-approaches-for-non-alcoholic-fatty-liver-disease
#7
Konstantinos Imprialos, Konstantinos Stavropoulos, Sofia Bouloukou, Georgios Kerpiniotis, Asterios Karagiannis, Michael Doumas
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, data on their efficacy in liver histology are not consistent. AIM: We discuss current treatment options for NAFLD and NASH and preliminary results from novel drugs under investigation...
2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676019/statins-an-under-appreciated-asset-for-the-prevention-and-the-treatment-of-nafld-or-nash-and-the-related-cardiovascular-risk
#8
Vasilios G Athyros, Chrysa Boutari, Konstantinos Stavropoulos, Panagiotis Anagnostis, Konstantinos P Imprialos, Michael Doumas, Asterios Karagiannis
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease (30% of the general population) and up to 40% of cases advance to the more severe form of the disease: nonalcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD). There is no generally accepted effective treatment for NAFLD/NASH. The joint guidelines of the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO) suggest the "off label" use of pioglitazone in patients without type 2 diabetes mellitus (T2DM) and pioglitazone in subjects with T2DM or vitamin E or their combination for the treatment of NASH; however pioglitazone has considerable limitations: weight gain, bone fractures in women, and heart failure...
2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28575232/liver-safety-of-statins-in-prediabetes-or-t2dm-and-nonalcoholic-steatohepatitis-post-hoc-analysis-of-a-randomized-trial
#9
RANDOMIZED CONTROLLED TRIAL
Fernando Bril, Paola Portillo Sanchez, Romina Lomonaco, Beverly Orsak, Joan Hecht, Fermin Tio, Kenneth Cusi
Context: Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity. Objective: To prospectively assess the long-term safety of statins in patients with prediabetes/type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis (NASH). Design: Post hoc analysis of statin use during a randomized, controlled trial assessing pioglitazone vs placebo for NASH...
August 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28521870/the-use-of-statins-alone-or-in-combination-with-pioglitazone-and-other-drugs-for-the-treatment-of-non-alcoholic-fatty-liver-disease-non-alcoholic-steatohepatitis-and-related-cardiovascular-risk-an-expert-panel-statement
#10
REVIEW
Vasilios G Athyros, Theodore K Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S Ganotakis, John Goudevenos, Moses S Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S Rallidis, Dimitrios Richter, Apostolos G Tsapas, Alexandros D Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G Vasiliadis, Charalambos Vlachopoulos, Dimitri P Mikhailidis, Christos Mantzoros
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. It is closely related to the epidemic of obesity, metabolic syndrome or type 2 diabetes mellitus (T2DM). NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular cancer (HCC). Nevertheless, cardiovascular disease (CVD) is the most common cause of death in NAFLD/NASH patients...
June 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28494529/nash-therapy-omega-3-supplementation-vitamin-e-insulin-sensitizers-and-statin-drugs
#11
REVIEW
Stephen Caldwell
Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD). NASH can progress to hepatic fibrosis, cirrhosis, portal hypertension and primary liver cancer. Therapy is evolving with a substantial number of trials of promising new agents now in progress. In this article however, we will examine data for several older forms of therapy which have been fairly extensively studied over the years: Polyunsaturated Fatty Acid (PUFA) supplements, vitamin E, insulin sensitizing agents with a focus on pioglitazone and statin agents...
June 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28240967/multicenter-phase-iii-randomized-double-blind-placebo-controlled-trial-of-pravastatin-added-to-first-line-standard-chemotherapy-in-small-cell-lung-cancer-lungstar
#12
RANDOMIZED CONTROLLED TRIAL
Michael J Seckl, Christian H Ottensmeier, Michael Cullen, Peter Schmid, Yenting Ngai, Dakshinamoorthy Muthukumar, Joyce Thompson, Susan Harden, Gary Middleton, Kate M Fife, Barbara Crosse, Paul Taylor, Stephen Nash, Allan Hackshaw
Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies delay relapse and prolong life in several cancer types. To our knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patients with cancer, specifically SCLC. Patients and Methods Patients with confirmed SCLC (limited or extensive disease) and performance status 0 to 3 were randomly assigned to receive daily pravastatin 40 mg or placebo, combined with up to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or intolerable toxicity...
May 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27634010/statins-improve-nash-via-inhibition-of-rhoa-and-ras
#13
Robert Schierwagen, Lara Maybüchen, Kanishka Hittatiya, Sabine Klein, Frank E Uschner, Tarcio T Braga, Bernardo S Franklin, Georg Nickenig, Christian P Strassburg, Jogchum Plat, Tilman Sauerbruch, Eicke Latz, Dieter Lütjohann, Sebastian Zimmer, Jonel Trebicka
Nonalcoholic steatohepatitis (NASH), especially as part of the metabolic syndrome (MS), is an increasing burden in Western countries. Statins are already used in MS and seem to be beneficial in liver diseases. The aim of this study was to investigate the molecular mechanisms underlying pleiotropic effects on small GTPases of statins in NASH. NASH within MS was induced in 12-wk-old apoE(-/-) mice after 7 wk of Western diet (NASH mice). Small GTPases were inhibited by activated simvastatin (SMV), NSC23766 (NSC), or Clostridium sordellii lethal toxin (LT) by using subcutaneous osmotic minipumps...
October 1, 2016: American Journal of Physiology. Gastrointestinal and Liver Physiology
https://www.readbyqxmd.com/read/27627804/epicardial-adipose-tissue-eat-thickness-is-associated-with-cardiovascular-and-liver-damage-in-nonalcoholic-fatty-liver-disease
#14
Anna Ludovica Fracanzani, Giuseppina Pisano, Dario Consonni, Silvia Tiraboschi, Andrea Baragetti, Cristina Bertelli, Giuseppe Danilo Norata, Paola Dongiovanni, Luca Valenti, Liliana Grigore, Tatiana Tonella, Alberico Catapano, Silvia Fargion
BACKGROUND AND AIMS: Epicardial adipose tissue (EAT) has been proposed as a cardiometabolic and hepatic fibrosis risk factor in patients with non alcoholic fatty liver disease (NAFLD). Aim of this study was to evaluate the role of EAT in NAFLD by analyzing 1) the association between EAT, the other metabolic parameters and the severity of steatosis 2) the relationship between cardiovascular (cIMT, cplaques, E/A), liver (presence of NASH and significant fibrosis) damage and metabolic risk factors including EAT 3) the relationship between EAT and genetic factors strongly influencing liver steatosis...
2016: PloS One
https://www.readbyqxmd.com/read/27110380/statins-antidiabetic-medications-and-liver-histology-in-patients-with-diabetes-with-non-alcoholic-fatty-liver-disease
#15
Fabio Nascimbeni, Judith Aron-Wisnewsky, Raluca Pais, Joan Tordjman, Christine Poitou, Frederic Charlotte, Pierre Bedossa, Thierry Poynard, Karine Clément, Vlad Ratziu
BACKGROUND: Type-2 diabetes mellitus (T2DM) is a risk factor for progressive non-alcoholic fatty liver disease (NAFLD). Drugs commonly prescribed in patients with T2DM may affect liver histology by interfering with lipid metabolism and insulin resistance/secretion. AIM: We studied if statins or antidiabetic agents were associated with non-alcoholic steatohepatitis (NASH) and significant fibrosis (SF). METHODS: We performed a cross-sectional study of 346 diabetics with biopsy-proven NAFLD...
2016: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/27105648/short-term-and-long-term-cardiovascular-risk-metabolic-syndrome-and-hiv-in-tanzania
#16
COMPARATIVE STUDY
Justin R Kingery, Yona Alfred, Luke R Smart, Emily Nash, Jim Todd, Mostafa R Naguib, Jennifer A Downs, Samuel Kalluvya, Johannes B Kataraihya, Robert N Peck
OBJECTIVE: To compare short-term and long-term cardiovascular disease (CVD) risk scores and prevalence of metabolic syndrome in HIV-infected adults receiving and not receiving antiretroviral therapy (ART) to HIV-negative controls. METHODS: A cross-sectional study including 151 HIV-infected, ART-naive, 150 HIV-infected on ART and 153 HIV-negative adults. Traditional cardiovascular risk factors were determined by standard investigations. The primary outcome was American College of Cardiology/American Heart Association Atherosclerotic CVD (ASCVD) Risk Estimator lifetime CVD risk score...
August 1, 2016: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/27098507/statins-increase-mitochondrial-and-peroxisomal-fatty-acid-oxidation-in-the-liver-and-prevent-non-alcoholic-steatohepatitis-in-mice
#17
Han Sol Park, Jung Eun Jang, Myoung Seok Ko, Sung Hoon Woo, Bum Joong Kim, Hyun Sik Kim, Hye Sun Park, In Sun Park, Eun Hee Koh, Ki Up Lee
BACKGROUND: Non-alcoholic fatty liver disease is the most common form of chronic liver disease in industrialized countries. Recent studies have highlighted the association between peroxisomal dysfunction and hepatic steatosis. Peroxisomes are intracellular organelles that contribute to several crucial metabolic processes, such as facilitation of mitochondrial fatty acid oxidation (FAO) and removal of reactive oxygen species through catalase or plasmalogen synthesis. Statins are known to prevent hepatic steatosis and non-alcoholic steatohepatitis (NASH), but underlying mechanisms of this prevention are largely unknown...
October 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/26810159/correlation-between-non-alcoholic-fatty-liver-disease-nafld-and-dyslipidemia-in-type-2-diabetes
#18
Saini Krishan
Non-alcoholic fatty liver means the presence of hepatosteatosis without significant alcohol consumption; it is strongly associated with obesity and metabolic disorder like type 2 diabetes and dyslipideamia. NASH may progress to advanced stages of hepatic fibrosis and cirrhosis. Increased body mass index and viral genotype contribute to steatosis in chronic hepatitis. The sonographic features of NAFLD include the presence of bright hepatic echotexture deep attenuation, and vascular blurring either singly or in combination...
April 2016: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/26288848/reduced-lysosomal-acid-lipase-activity-in-adult-patients-with-non-alcoholic-fatty-liver-disease
#19
Francesco Baratta, Daniele Pastori, Maria Del Ben, Licia Polimeni, Giancarlo Labbadia, Serena Di Santo, Fiorella Piemonte, Giulia Tozzi, Francesco Violi, Francesco Angelico
Non-alcoholic fatty liver disease (NAFLD) is characterized by intra-hepatic fat accumulation and mechanisms involved in its pathogenesis are not fully explained. Lysosomal Acid Lipase (LAL) is a key enzyme in lipid metabolism. We investigated its activity in patients with fatty liver. LAL activity (nmol/spot/h) was measured in 100 adult healthy subjects (HS) and in 240 NAFLD patients. A sub-analysis on 35 patients with biopsy-proven non-alcoholic steatohepatitis (NASH) was performed. Median LAL activity was 1...
July 2015: EBioMedicine
https://www.readbyqxmd.com/read/26181068/nonalcoholic-fatty-liver-disease-from-lipid-profile-to-treatment
#20
Kouichi Miura, Hirohide Ohnishi
Nonalcoholic fatty liver disease (NAFLD) is characterized by excess lipid accumulation in the liver. Although the majority of NAFLD is benign simple steatosis, a subset of NAFLD includes nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and liver cancer. In both simple steatosis and steatohepatitis, triglyceride is well known as the major lipid that accumulates in the liver. However, we have little information on the other lipids that deposit in the liver. Thus, lipid profiling is necessary to understand the pathogenesis of NAFLD...
October 2012: Clinical Journal of Gastroenterology
keyword
keyword
165242
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"